Salemonline Journal

DelveInsight Estimates a Diverse IgA Nephropathy Pipeline Comprising 30+ Companies Working in the Domain

 Breaking News
  • No posts were found

DelveInsight Estimates a Diverse IgA Nephropathy Pipeline Comprising 30+ Companies Working in the Domain

March 06
20:52 2023
DelveInsight Estimates a Diverse IgA Nephropathy Pipeline Comprising 30+ Companies Working in the Domain

DelveInsight’s, “IgA Nephropathy Pipeline Insight, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy pipeline drug profiles, including IgA Nephropathy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For IgA Nephropathy Emerging drugs, the IgA Nephropathy pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The IgA Nephropathy pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the IgA Nephropathy Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, IgA Nephropathy clinical trials studies, IgA Nephropathy NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the IgA Nephropathy Pipeline Report

 

  • DelveInsight’s IgA Nephropathy Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.

 

  • The leading IgA Nephropathy Companies include Aravive, Aduro BioTech, Alnylam Pharmaceuticals, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, and others.

 

  • Promising IgA Nephropathy Pipeline Therapies include Omega-3 fatty acid ethylester90, Budesonide, Tacrolimus, BION-1301, NEFECON, Blisibimod, RC18 160mg, LNP023, and others.

 

  • The IgA Nephropathy companies and academics are working to assess challenges and seek opportunities that could influence IgA Nephropathy R&D. The IgA Nephropathy pipeline therapies under development are focused on novel approaches to treat/improve IgA Nephropathy.

 

Request a sample and discover the recent breakthroughs happening in the IgA Nephropathy Pipeline landscape @ IgA Nephropathy Pipeline Outlook Report

 

IgA Nephropathy Overview

IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is not known what causes IgA deposits in the glomeruli. In more than 10% of affected families, it is inherited. Each person may have a different set of signs and symptoms from IgAN. The Most common symptoms are: Hematuria and Proteinuria, Swelling in ankles and High Blood pressure. Urine test, Blood test, Glomerular Filtration rate, Kidney Biopsy are some of the procedures that helps in the diagnosis of IgA Nephropathy. There is no cure for IgA nephropathy, but treatments can help to prevent more damage to your kidneys.

 

Recent Developmental Activities in the IgA Nephropathy Treatment Landscape

 

  • On November 7, 2022, Ionis Pharmaceuticals, Inc. presented positive results from a Phase 2 clinical study of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN). Results from the study were presented in a poster session at the American Society of Nephrology’s (ASN) Kidney Week 2022.

 

  • On November 05, 2022, Vera Therapeutics, Inc. announced new clinical data presented on the Company’s two product candidates, atacicept in immunoglobulin A nephropathy (IgAN) and MAU868 in kidney transplant. These data were presented in poster and oral presentations, respectively, at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting, held November 3-6, 2022, in Orlando, Florida.

 

  • In October 2022, Transcenta Holding Limited announced that TST004, its best-in-class, humanized monoclonal antibody targeting MASP2, had received IND clearance from the U.S. Food and Drug Administration (FDA). MASP2, mannose-binding protein-associated serine protease 2, is a key enzyme in the lectin pathway initiation of complement activation. Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantation–associated thrombotic microangiopathy (HSCT-TMA). Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.

 

  • In September 2022, Eledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the company’s Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).

 

  • In August 2022, Alnylam Pharmaceuticals, Inc. announced positive results from a Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in development in collaboration with Regeneron Pharmaceuticals for the treatment of adult patients with immunoglobulin A nephropathy (IgAN). The results were presented at the 18th European Meeting on Complement in Human Disease (EMCHD), being held in Bern, Switzerland, on August 26-28.

 

  • In August 2022, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

 

  • In July 2022, Chinook Therapeutics, Inc. announced the European Commission had granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). The decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).

 

For further information, refer to the detailed IgA Nephropathy Drugs Launch, IgA Nephropathy Developmental Activities, and IgA Nephropathy News, click here for IgA Nephropathy Ongoing Clinical Trial Analysis

 

IgA Nephropathy Emerging Drugs Profile

 

  • Atrasentan: Chinook Therapeutics

Atrasentan is a potent and selective, small molecule inhibitor of the endothelin A receptor for the potential treatment of IgA Nephropathy (IgAN) and other proteinuric glomerular diseases. Chinook Therapeutics has initiated a phase III trial (ALIGN) of Atrasentan in early 2021 in patients with IgAN at high risk of kidney function decline.

 

  • Sparsentan: Travere Therapeutics

Sparsentan is a novel small-molecule candidate in Phase III development for the treatment of IgA nephropathy (IgAN). IgAN, also called Berger’s disease, is a type of glomerulonephritis. Sparsentan is a single molecule designed to selectively block the receptors of two pathways which are associated with kidney disease progression. The receptors are endothelin 1A and angiotensin II type 1. In March 2022, Travere Therapeutics, Inc.  announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

 

IgA Nephropathy Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for IgA Nephropathy. The companies which have their IgA Nephropathy drug candidates in the most advanced stage, i.e. Preregistration include, Travere Therapeutics.

 

IgA Nephropathy Pipeline Segmentation

 

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

  • Monoclonal Antibody
  • Peptides 
  • Polymer 
  • Small molecule
  • Gene therapy

 

Find out more about the IgA Nephropathy Pipeline Segmentation, Therapeutics Assessment, and IgA Nephropathy Emerging Drugs @ IgA Nephropathy Treatment Landscape

 

Scope of the IgA Nephropathy Pipeline Report

 

  • Coverage- Global

 

  • IgA Nephropathy Companies- Aravive, Aduro BioTech, Alnylam Pharmaceuticals, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, and others.

 

  • IgA Nephropathy Pipeline Therapies- Omega-3 fatty acid ethylester90, Budesonide, Tacrolimus, BION-1301, NEFECON, Blisibimod, RC18 160mg, LNP023, and others.

 

  • IgA Nephropathy Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for IgA Nephropathy Pipeline Companies and Therapies, click here @ IgA Nephropathy Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. IgA Nephropathy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Pregistration)
  7. Sparsentan: Travere Therapeutics
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Drug Name: Company Name
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I)
  13. Drug Name: Company Name
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. IgA Nephropathy Key Companies
  17. IgA Nephropathy Key Products
  18. IgA Nephropathy- Unmet Needs
  19. IgA Nephropathy- Market Drivers and Barriers
  20. IgA Nephropathy- Future Perspectives and Conclusion
  21. IgA Nephropathy Analyst Views
  22. IgA Nephropathy Key Companies
  23. Appendix

 

Got Queries? Find out the related information on IgA Nephropathy Mergers and acquisitions, IgA Nephropathy Licensing Activities @ IgA Nephropathy Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles